MyMD Pharmaceuticals Seeks $100 Million in New Funding for Quantum Computing Pivot

MyMD Pharmaceuticals, now operating as Q/C Technologies, has taken a significant step to fund its dramatic strategic shift. The company filed a shelf registration statement with U.S. regulators, seeking authorization to raise up to $100 million through the future sale of various securities.

The shelf registration provides Q/C Technologies with flexible access to capital markets. This mechanism allows the firm to sell common stock, preferred shares, warrants, or debt instruments in one or more offerings over time, as needed. Management states this financial maneuverability is intended to advance its new core business: developing high-performance, quantum-based laser computing infrastructure for cryptocurrency applications.

From Drug Development to Blockchain Tech

The company’s journey to this point involves a complete reinvention. Originally known as MyMD Pharmaceuticals, it first changed its name to TNF Pharmaceuticals in July 2024. A second, more definitive rebranding occurred in September 2025 to Q/C Technologies, cementing its exit from biopharma and entry into the energy-efficient blockchain infrastructure sector.

Central to this new direction is an exclusive license for LightSolver’s Laser Processing Units (LPUs). The company claims this technology can perform complex computations at the speed of light while consuming up to 90% less power than traditional systems. If successful, it would address a critical industry challenge: the massive and growing energy demands of cryptocurrency mining and blockchain operations.

Should investors sell immediately? Or is it worth buying MyMD Pharmaceuticals?

Key Details of the Strategic Shift:
* Funding Vehicle: A $100 million universal shelf registration for equity, debt, and warrants.
* Core Focus: Quantum laser computing hardware tailored for the crypto sector.
* Proprietary Edge: Exclusively licensed LightSolver LPU technology.

Evaluating the Pharmaceutical Legacy

As Q/C Technologies charges ahead in computing, it is reassessing its pharmaceutical origins. The company’s management is currently reviewing strategic options for its remaining drug programs, Isomyosamine and Supera-CBD. A potential sale or spin-off of these assets could generate additional capital to further accelerate the development of its quantum laser infrastructure.

With the potential for $100 million in new funding, the focus is squarely on scaling its LPU technology operationally. The ultimate test will be whether the promised efficiency gains materialize in real-world applications, allowing the company to secure a lasting position in the intensely competitive high-performance computing market.